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Abstract
Background: Molecular epidemiological studies have shown that gene polymorphisms of vitamin
D receptor (VDR) are associated with prostate cancer risks. However, previous results from many
molecular studies remain inconsistent.
Methods: Blood samples were collected from 122 prostate cancer patients and 130 age-matched
control subjects in the Han population of Southern China. The differences of VDR  gene
polymorphism between cancer cases and controls were determined by PCR-RFLP, examiming FokI
(exon 2), BsmI, Tru9I, ApaI (intron 9), and TaqI (exon 9). Associations between the VDR gene
polymorphism and prostate cancer risk were calculated in an unconditional logistic regression
model. Linkage disequilibrium and haplotypes were analyzed with the SHEsis software.
Results: Of five polymorphisms, BsmI was shown to associate with prostate cancer, while FokI,
Tru9I, ApaI, and TaqI did not show any significant association. After adjustment for age, the BsmI 'B'
allele was associated with an almost 1/3-fold risk (OR = 0.35, 95%CI: 0.15-0.80) of the occurrence
of prostate cancer, a 1/5-fold risk (OR = 0.20, 95%CI: 0.06-0.68) of poorly differentiated prostate
cancer, and a 1/10-fold risk (OR = 0.10, 95%CI: 0.01-0.78) of aggressive prostate cancer compared
with the 'b' allele, especially among older men (>71 years). In addition, haplotype analysis revealed
that the 'F-b-U-A-T' was more frequent found in cases than in controls (3.4% vs 0.0%, P = 0.0035),
while the frequency of haplotype 'F-B-U-a-T' was 0.8% in cases, significantly lower than in controls
(3.9%, P = 0.019).
Conclusion: Our experiments provide evidences that genetic polymorphisms in the VDR gene
may be potential risk factors for prostate cancer in the Han population of southern China and the
susceptibility to prostate cancer is associated with ethnicity and geographic location.
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Background
Prostate cancer is the most common type of tumor in old
men throughout the world. In 2003, about 220,900 new
cases of prostate cancer were diagnosed in the United
States [1]. Although epidemiological studies showed that
the incidence of prostate cancer in Asians is much lower
than that in African-Americans [2], the occurrence of this
disease has rapidly increased among Chinese men [3]. In
the Shanghai population, the incidence was 1.9/10 mil-
lion in 1983, but it increased to 21.08/10 million in 2005
[4]. The incidence rate in Beijing was similar to that of
Shanghai [5]. Age, race, and geographical factors are well-
established risk factors of prostate cancer [6]. However,
these factors may not completely explain the differences
between different ethnic groups in prostate cancer rates.
Therefore, genetic variation in certain genes, including
genes controlling vitamin D activity, could play a role in
determination of susceptibility to prostate cancer.
Based on investigations of the differences in prostate can-
cer incidence at different latitudes in the United States,
Schwartz et al. [7,8] hypothesized that low ultraviolet
exposure may be a risk factor for prostate cancer. After
exposure to UV radiation, vitamin D is produced in the
skin and then hydroxylated in the liver to 25-hydroxyvita-
min D3, and in the kidneys to the more physiologically
active metabolite 1α,25-dihydroxyvitamin D3
[1,25(OH)2D3]. The biological activity of 1,25(OH)2D3 is
mediated primarily by vitamin D receptor (VDR). In addi-
tion to kidney and bone cells, VDR [9] is also expressed in
human prostatic cells, and a series of experiments revealed
that VDR mediates the influence of 1,25(OH)2D3 on the
growth, differentiation [10,11], and apoptosis [12] of pro-
static cells. These findings indicated that 1,25(OH)2D3
and its specific nuclear receptor protein, VDR, may be
closely associated with prostate cancer risk.
The expression and function of VDR may be influenced by
VDR  gene polymorphisms. Polymorphisms (intron 8,
exon 9, and polyA microsatellite, Figure 1) in the 3' end
may correlate with gene transcription [13]. In exon 2 of 5'
end, the FokI F allele may lack the first start codon [14],
resulting in a VDR protein that is shortened by three
amino acids [15]. This protein variant was shown to be
more efficient at transactivating a vitamin D-regulated tar-
get gene [16]. Polymorphic variants of the VDR gene have
been suggested to be associated with prostate cancer risk
and/or a more aggressive phenotype [17,18]. Gene poly-
morphisms have been reported to be of significant rele-
vance with cancer risk in many different populations [17-
Positions of polymorphisms in the vitamin D receptor gene Figure 1
Positions of polymorphisms in the vitamin D receptor gene.BMC Medical Genetics 2009, 10:125 http://www.biomedcentral.com/1471-2350/10/125
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26]. Since there is a series of VDR gene polymorphisms
that are in strong linkage disequilibrium with one
another, some VDR haplotypes have also been reported to
be linked with prostate cancer [27,28]. However, other
studies [29-33] did not show such significant associa-
tions. The inconsistent results were probably due to differ-
ences in the study populations [20,22].
In this report, we carried out a population-based, case-
control study to evaluate the association between VDR
gene polymorphisms and prostate cancer risk in the Han
population of Southern China because one salient charac-
teristic of China's population has a large base with diverse
genetic backgrounds. The present study can provide a plat-
form to help explain the pathological mechanism of pros-
tate cancer and to a better understanding of the
geographic and ethnic differences associated with disease
incidence and mortality.
Methods
Subjects
In the present study, 122 prostate cancer patients and 130
age-matched male controls were enrolled in four hospitals
in southern China between March 2007 and August 2008.
All prostate cancer cases were confirmed by pathological
examination. The pathologic grades were classified
according to the Gleason score as well and moderately dif-
ferentiated (Gleason 2-6) and poorly differentiated
(Gleason 7-10) [34]. Based on the TNM classification sys-
tem promulgated by the American Joint Committee on
Cancer, the disease stage was divided into localized and
aggressive cancer, as determined by transrectal ultra-
sound, magnetic resonance imaging (MRI) and emission
computed tomography (ECT). Localized prostate cancer
can be detectable clinically or felt (palpated) on examina-
tion, but has not spread outside the prostate. Aggressive
cancer means the cancer has spread through the prostatic
capsule (eg, bladder neck, external sphincter, rectum, and
levator muscles) and even has invaded other nearby struc-
tures (eg, bone and pancreas).
The age-matched control subjects were individuals
recruited from retired employees at the First Affiliated
Hospital of Wenzhou Medical College. The controls were
screened to ensure that there had never been diagnosed
with cancer and had low plasma prostate-specific antigen
(PSA) levels (total PSA<4.00 ng/ml). The controls were
also checked for cancer history based on their past medi-
cal records and/or asked directly for their cancer history.
All subjects were informed about the contents of the study
and gave their informed consent. This study was approved
by the Ethics Committee of Wenzhou Medical College.
Molecular analysis
Blood samples were collected with the anticoagulant
EDTA K2  and stored at -20°C. Genomic DNA was
extracted using a DNA Extraction Kit (TaKaRa Bio Group,
Japan) and stored at 4°C. VDR polymorphisms were gen-
otyped by PCR-RFLP and the condition was displayed in
the Table 1. To control the experiments, a total of 80 sam-
ples were randomly selected and genotyped and con-
firmed by DNA sequencing by a second investigator.
FokI, BsmI, Tru9I, ApaI, and TaqI, are reported according to
the standard nomenclature in which lowercase and upper-
case letters indicate the presence or absence of a restriction
site, respectively. The FokI T and C alleles are represented
by f and F, the BsmI G and A alleles by b and B, the Tru9I
G and A alleles by U and u, the ApaI T and G alleles by A
and a, and the TaqI T and C alleles by T and t, respectively.
Statistical analysis
Tests for Hardy-Weinberg equilibrium were performed
separately for each SNP among case and control subjects.
The Independent-Samples T test was used to determine
differences according to age, and the chi-square or Fisher's
exact test was performed to calculate the clinical paramet-
ric distributions. Unconditional logistic regression analy-
sis models were used to evaluate the relationships
between different genotypes and disease risk [Odds ratios
Table 1: PCR-RFLP conditions for VDR gene polymorphisms (GenBank AY342401)
SNP Primer Base change Annealing temperature Restriction enzyme
FokI 5'AGCTGGCCCTGGCACTGACTCTGCTCT3'(F) C/T 61°C Fok I
5'ATGGAAACACCTTGCTTCTTCTCCCTC 3'(R)
BsmI 5'CAACCAAGACTACAAGTACCGCGTCAGTGA3'(F) G/A 57°C Mva1269 I
5'AACCAGCGGGAAGAGGTCAAGGG3'(R)
Tru9I 5'CAACCAAGACTACAAGTACCGCGTCAGTGA3'(F) G/A 57°C Tru1 I
5'AACCAGCGGGAAGAGGTC AAGGG3'(R)
ApaI 5'CAGAGCATGGACAGGGAGCAA3'(F) G/T 60°C Apa I
5'GCAACTCCTCATGGCTGAGGTCTC3'(R)
TaqI 5'CAGAGCATGGACAGGGAGCAA3'(F) T/C 60°C Taq I
5'GCAACTCCTCATGGCTGAGGTCTC3'(R)BMC Medical Genetics 2009, 10:125 http://www.biomedcentral.com/1471-2350/10/125
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(OR), 95% confidence intervals (95% CI)] adjusted by
age. Linkage disequilibrium and haplotypes were ana-
lyzed with the SHEsis software [35]. A p-value of less than
0.05 was considered as statistically significant.
Results and Discussion
The worldwide incidence of clinical prostate cancer shows
a strong dependence on age, race, and geography. For
example the incidence in African-Americans was signifi-
cantly higher than that in Asians, especially in the Chinese
population. Recent epidemiological studies in different
populations have indicated that difference in VDR geno-
type frequencies may play an important role in the risk of
prostate cancer. In the present study, we evaluated the
association between five polymorphisms in the VDR gene
and prostate cancer risk in the southern Chinese Han pop-
ulation.
Table 2 shows the demographic and clinical characteris-
tics of the subjects (122 prostate cancer patients and 130
non-cancer controls). No significant differences in age,
smoking status, or alcohol intake were observed between
cases and controls. In the present study, five polymor-
phisms, including FokI at the 5' end of exon 2, and BsmI,
Tru9I, ApaI, and TaqI in the 3'UTR region, were evaluated,
and each SNP was in Hardy-Weinberg equilibrium. Statis-
tical analysis revealed a significant difference in the allelic
frequencies of the BsmI genotype (Table 3), while other
polymorphisms did not show any significant differences.
Compared with BsmI 'bb', subjects with 'BB' and 'Bb' gen-
otypes were associated with a decreased risk (OR = 0.35,
95%CI: 0.15-0.81, P = 0.015). The BsmI 'B' allelic fre-
quency was 3.7% in cancer patients, which was signifi-
cantly lower than that of controls (8.5%), indicating a
decreased disease risk associated with this allele (OR =
0.35, 95%CI: 0.15-0.80, P = 0.013). To evaluate the asso-
ciation modified by the age, we stratified the age to two
groups (>71 and 71 years). Among the elderly men, the
OR value for the "B" allele was 0.09 (95%CI: 0.01-0.68)
versus the "b" allele (Table 4), and the OR value was 0.64
(95%CI: 0.25-1.66) among the younger men, suggesting
that the elder men with the "B" allele had lower risk of
prostate cancer. In addition, when stratifying our material
according to Gleason score and TNM classification, a
number of significant results were found. The 'B' allele
(compared to the 'b' allele) was also associated with a
decreased risk of aggressive (OR = 0.10, 95%CI: 0.01-0.78,
P = 0.028) and poorly differentiated cancer (OR = 0.20,
95%CI: 0.06-0.68, P = 0.010, Table 4). Considering the
number of cases with the variant allele for most of these
strata is too small, and future research needs to further
expand the sample size to confirm these results.
Based on observations of the distribution difference
between prostate cancer cases and controls, we here
hypothesize the BsmI 'B' allele might have a protective
effect against tumorigenesis. Previous studies also found
that the BsmI 'BB+Bb' genotype was associated with one-
third the risk of prostate cancer in a Japanese population
[20] and one-fifth the risk in advanced stages and in
poorly differentiated disease in a Taiwanese population
[36]. Although Ma et al. [37] reported no significant asso-
ciation between the BsmI polymorphism and prostate
cancer risk, they did find a 57% reduction in the risk of
prostate cancer with the BsmI 'BB' genotype compared
with the 'bb' genotype in American men. These data also
support our findings concerning the protective effect of
the BsmI 'B' allele. However, there are still some studies
Table 2: Clinic and demographic characteristics of the subjects
Cases (n = 122) Controls (n = 130) OR(95%CI) P value
Ages at diagnosis (year)a 71.77 ± 8.12 71.28 ± 7.86 0.632
< 60 11 (9.0%) 11 (8.5%)
60~69 33 (27.1%) 42 (32.3%)
70~79 56 (45.9%) 59 (45.4%)
≥ 80 22 (18.0%) 18 (13.8%)
Smoking status b
Nonsmoking 82 (67.2%) 91(70.0%) 1.138(0.668-1.939) 0.634
Smoking 40 (32.8%) 39(30.0%)
Alcohol intake b
No alcohol 62 (50.8%) 69 (53.1%) 1.095(0.668-1.795) 0.720
Drinking 60 (49.2%) 61 (46.9%)
Gleason score
< 7 43 (35.2%)
≥ 7 79 (64.8%)
TNM classification
Localized 72 (59.0%)
Aggressive 50 (41.0%)
a, Data are expressed as mean ± standard deviation (SD), P values are calculated using unpaired t-test;
b, Based on chi-square test.BMC Medical Genetics 2009, 10:125 http://www.biomedcentral.com/1471-2350/10/125
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failed to show such a result. For example, studies such as
Liu et al. [32] in Beijing population and Ingles et al. [28]
in African-Americans. In addition to ethnic characteristics,
geographical differences and living habits, the factors,
including the study sample size, the choice of the control
group (BPH or healthy people), might be the important
reasons for these inconsistent results.
Although the BsmI polymorphic variant is in the untrans-
lated intron 8 and does not seem to alter the VDR amino
acid sequence, some studies have reported that the BsmI
'BB' genotype is significantly associated with higher
plasma 1,25(OH)2D3 (median = 36.2 pg/ml for the 'BB'
versus 33.9 pg/ml for the 'bb' genotype; P = 0.02), suggest-
ing that the BsmI polymorphic variant is associated with
VDR function [37]. In fact, strong linkage disequilibrium
was detected among four polymorphisms, including BsmI
in the 3'UTR region (Table 5), which is consistent with
other studies [13,18,36,38]. In addition, the effect of BsmI
may be influenced by other polymorphisms.
Haplotypes with five-locus (FokI, BsmI, Tru9I, ApaI, and
TaqI) of VDR  gene polymorphisms were also analyzed
with SHEsis software. We found that the haplotype 'F-b-U-
Table 4: Age-adjusted ORs and P value in different kinds of patients compared with controls by BsmI polymorphisms
Pathological grade Clinic stage Age stratification (years)*
Controls Well-
mod
OR
(95%CI)
Poorly OR
(95%CI)
Localized OR
(95%CI)
Aggressive OR
(95%CI)
>71 OR
(95%CI)
71 OR
(95%CI)
bb 108 38 1.00
(referent)
76 1.00
(referent)
65 1.00
(referent)
49 1.00
(referent)
62 1.00
(referent)
52 1.00
(referent)
Bb 21 5 1.44
(0.51-4.11)
30 . 2 0
(0.06-0.71)
70 . 5 6
(0.23-1.40)
10 . 1 1
(0.01-0.81)
10 . 0 8
(0.01-0.64)
70 . 7 3
(0.26-2.04)
BB 10 0 0 0 0 0
Bb+ BB 22 5 0.97
(0.93-1.02)
30 . 1 9
(0.06-0.67)
70 . 5 4
(0.22-1.33)
10 . 1 0
(0.01-0.77)
10 . 0 8
(0.01-0.64)
70 . 6 7
(0.25-1.85)
b 237 81 1.00
(referent)
155 1.00
(referent)
137 1.00
(referent)
99 1.00
(referent)
125 1.00
(referent)
109 1.00
(referent)
B 23 5 0.97
(0.94-1.00)
30 . 2 0
(0.06-0.68)
70 . 5 3
(0.22-1.28)
10 . 1 0
(0.01-0.78)
10 . 0 9
(0.01-0.68)
70 . 6 4
(0.25-1.66)
*, Stratified by the average age of 71 years.
Table 3: Distribution of VDR genotypes and alleles between prostate cancer cases and controls
Cases (freq) Controls (freq) OR(95%CI) P value
FokI FF 33 (0.270) 38 (0.292) 1.00(referent)
Ff 63 (0.517) 55 (0.423) 1.317(0.730-2.376) 0.361
ff 26 (0.213) 37 (0.285) 0.815(0.411-1.620) 0.560
F 129 (0.529) 131 (0.504) 1.00(referent)
f 115 (0.471) 129 (0.496) 0.910(0.641-1.291) 0.597
BsmI bb 114 (0.934) 108 (0.831) 1.00(referent)
Bb 8 (0.066) 21 (0.162) 0.362(0.154-0.853) 0.020
BB * 0 (0) 1 (0.008) - -
b 236 (0.964) 237 (0.912) 1.00(referent)
B 8 (0.036) 23 (0.088) 0.351(0.154-0.800) 0.013
Tru9I UU 76 (0.623) 78 (0.600) 1.00(referent)
Uu 41 (0.336) 47 (0.362) 0.902(0.533-1.525) 0.699
uu 5 (0.041) 5 (0.038) 1.039(0.289-3.742) 0.953
U 193 (0.791) 203 (0.781) 1.00(referent)
u 51 (0.209) 57 (0.219) 0.947(0.618-1.452) 0.804
ApaI AA 10 (0.082) 9 (0.069) 1.00(referent)
Aa 56 (0.459) 61 (0.469) 0.800(0.300-2.128) 0.654
aa 56 (0.459) 60 (0.462) 0.810(0.304-2.160) 0.673
A 76 (0.311) 79 (0.304) 1.00(referent)
a 168 (0.689) 181 (0.696) 0.956(0.654-1.397) 0.814
TaqI TT 112 (0.918) 121 (0.931) 1.00(referent)
Tt 10 (0.082) 9 (0.069) 1.213(0.475-3.098) 0.687
tt 0 (0) 0 (0) - -
T 234 (0.959) 251 (0.965) 1.00(referent)
t 10 (0.041) 9 (0.035) 1.204(0.480-3.016) 0.693
*, Genotype (BB+Bb) vs bb, OR age-adjusted = 0.346, 95%CI: 0.148-0.811, P = 0.015.BMC Medical Genetics 2009, 10:125 http://www.biomedcentral.com/1471-2350/10/125
Page 6 of 8
(page number not for citation purposes)
A-T' was more frequent in cases than in controls (3.4% vs.
0.0%, P = 0.0035; Table 6), while the frequency of haplo-
type 'F-B-U-a-T' was 0.8% in cases, significantly lower
than that in controls (3.9%, P = 0.019), indicating that the
haplotype 'F-b-U-A-T' was associated with increased risk
of prostate cancer and the 'F-B-U-a-T' with a decreased
risk. In Caucasian and African-Americans, an association
was observed between disease risk and the four-locus 'F-B-
A-t' haplotype (OR = 0.48, 95%CI: 0.30-0.76) compared
with the 'F-b-a-T' haplotype, as reported by Cicek et al.
[27]. The haplotype results obtained in that study also
partly support our conclusion. In addition to BsmI, link-
age disequilibrium data also showed that other polymor-
phisms (Tru9I, ApaI, and TaqI) may play some role in
disease risk through their interactions. Taylor et al. [17]
reported that the TaqI 'tt' genotype is significantly
decreased in prostate cancer patients (8%) compared to
noncancer controls in Caucasian Americans (22%; OR =
0.32; 95%CI: 0.15-0.75). A study of a southern European
population also showed an association of the TaqI 'T
'allele with cancer risk [22]. However, our study showed
that these polymorphisms demonstrated no significant
differences in the southern Chinese Han population,
which also suggested that the distribution of VDR gene
polymorphisms may be associated with ethnicity and/or
location.
The distribution of polymorphisms in the 3'UTR region of
the VDR gene may be relavant with VDR mRNA stability
and gene transcription [13]. Alterations in the ability of
VDR protein to bind 1,25(OH)2D3 or activate the VDRE
gene would ultimately result in changes in the expression
of regulatory genes, such as CDK, which can directly or
indirectly control prostatic cell division. If the protective
Table 6: Haplotype frequencies for VDR five polymorphisms between prostate cancer cases and controls
Haplotypes Controls (freq) Cases (freq) P valuea OR (95%CI)
F-b-U-A-T 0.00(0.000) 8.90(0.034) 0.0035 -
F-b-U-a-t 6.98(0.029) 5.29(0.020) - -
F-b-U-a-T 0.00(0.000) 1.94(0.007) - -
F-B-u-A-T 6.31(0.026) 4.31(0.017) - -
F-B-u-a-T 18.06(0.074) 17.75(0.068) 0.806 0.92 (0.46~1.82)
F-B-U-A-T 87.01(0.357) 90.69(0.349) 0.863 0.97 (0.67~1.41)
F-B-U-a-T 9.56(0.039) 2.03(0.008) 0.019 0.19 (0.04~0.89)
f-B-u-a-T 0.00(0.000) 1.65(0.006) - -
f-B-U-a-t 0.00(0.000) 2.66 (0.010) - -
f-b-U-a-T 0.00(0.000) 2.48(0.010) - -
f-B-u-A-T 1.54(0.006) 0.00(0.000) - -
f-B-u-a-T 25.09(0.103) 33.21(0.128) 0.376 1.28 (0.74~2.23)
f-B-U-A-T 72.11(0.296) 77.10(0.297) 0.970 1.01 (0.68~1.49)
f-B-U-a-t 1.00(0.004) 1.05(0.004) - -
f-B-U-a-T 14.32(0.059) 10.86 (0.042) 0.385 0.70 (0.31~1.57)
F-B-U-a-t 1.00(0.004) 0.00(0.000) - -
f-b-U-A-t 0.92(0.004) 0.00(0.000) - -
f-B-u-A-T 1.54(0.006) 0.00(0.000) - -
a, Based on Fisher's exact test;
All those frequency <0.10 will be ignored in analysis.
Table 5: Linkage disequilibrium test between five VDR gene polymorphisms
SNP1 SNP2 Distance between two polymorphisms D' P valuea
FokI BsmI 33060 0.513 0.110
FokI Tru9I 33220 0.096 0.803
FokI ApaI 34058 0.169 0.379
FokI TaqI 34138 0.299 0.739
BsmI Tru9I 160 0.574 0.253
BsmI ApaI 998 0.556 0.006
BsmI TaqI 1078 0.826 <0.001
Tru9I ApaI 838 0.831 <0.001
Tru9I TaqI 918 0.953 <0.001
ApaI TaqI 80 0.900 <0.001
a, Based on chi-square test.BMC Medical Genetics 2009, 10:125 http://www.biomedcentral.com/1471-2350/10/125
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action of the BsmI 'B' allele is confirmed experimentally,
the pathological mechanism of prostate cancer would be
better understand. In addition, we observed the genotype
and allelic frequencies of VDR gene varied from race to
race. For example, the allelic frequency of TaqI 'T' in the
southern Chinese Han population (96.5%, in control)
was significantly higher than that in white Americans
(55.2%) [17] and Portuguese (57.8%) [22]. Thus, the dis-
tribution of VDR gene polymorphisms may help explain
the difference in incidence of prostate cancer in different
populations.
Conclusion
In conclusion, the present study indicated that VDR gene
polymorphisms may be associated with prostate cancer
risk in the southern Chinese Han population, and these
associations may largely depend on population character-
istics and geographic location.
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